More articles from MTA II: Endocrine/Neuroendocrine Posters

You have access
Brown fat tissue imaging with 18F-FDG PET/CT and its relationship with central obesity and metabolic parameters in adult human
Min Zhang, Qidi Wang, Yun Xi and Biao Li

Journal of Nuclear Medicine May 1, 2013, 54 (supplement 2) 1898;
You have access
Altered biodistribution of FDG in patients with type-2 diabetes mellitus
Semra Ince, Alper Ozgur Karacalioglu, Ozdes Emer, Engin Alagöz, Bengul Gunalp, Nuri Arslan and Mehmet Ali Ozguven

Journal of Nuclear Medicine May 1, 2013, 54 (supplement 2) 1922;
You have access
FDG PET for neuroendocrine tumors: Comparison with adrenomedullary scintigraphy
Yuka Yamamoto, Fumitoshi Aga and Yoshihiro Nishiyama

Journal of Nuclear Medicine May 1, 2013, 54 (supplement 2) 1914;
You have access
Suspected hyperplastic parathyroid glands: Are they visualized on FDG-PET/CT in patients with end-stage renal disease?
Atsushi Tani, Yoriko Kajiya, Masanori Nakajo and Masayuki Nakajo

Journal of Nuclear Medicine May 1, 2013, 54 (supplement 2) 1913;
You have access
Clinical PET imaging of neuroendocrine tumors using 64Cu-DOTA-Tyr3-octreotate
Andreas Pfeifer, Camilla Bardram Johnbeck, Ulrich Knigge, Jann Mortensen, Peter Oturai, Annika Loft, Anne Berthelsen, Tina Binderup, Palle Rasmussen and Andreas Kjaer

Journal of Nuclear Medicine May 1, 2013, 54 (supplement 2) 1854;
You have access
Whole body retention of I-131 at 24hr vs 48hr as a predictor of maximum tolerated activity (MTA)
Frank Atkins, Douglas Van Nostrand, Michael Orquiza and Leonard Wartofsky

Journal of Nuclear Medicine May 1, 2013, 54 (supplement 2) 1857;
You have access
68Ga-DOTATATE uptake of ileal neuroendocrine tumors: Correlation with time to progression under treatment with sandostatin LAR 30
Julia Geisler, Christoph Auernhammer, Harun Ilhan, Peter Bartenstein, Marcus Hacker and Alexander Haug

Journal of Nuclear Medicine May 1, 2013, 54 (supplement 2) 1876;
You have access
Comparison of preablative thyroglobulin level with the other risk factors in determining papillary thyroid cancer prognosis
Elgin Ozkan, Yasemin Genc, Mine Araz, Cigdem Soydal, Gulseren Aras and Kemal Kir

Journal of Nuclear Medicine May 1, 2013, 54 (supplement 2) 1869;
You have access
Preablation serum thyroglobulin is the most predictive factor for successful I-131 therapy in differentiated thyroid cancer
Hee Jeong Park, Sang-Geon Cho, Sae-Ryung Kang, Jahae Kim, Su Woong Yoo, Ari Chong, Seong Young Kwon, Jung Joon Min, Ho-Chun Song and Hee-Seung Bom

Journal of Nuclear Medicine May 1, 2013, 54 (supplement 2) 1861;
You have access
Clinical standardized quantitative comparison of [⁶⁸Ga]Ga-DOTA-TOC and [⁶⁸Ga]Ga-DOTA-TATE
Jens Sörensen, Irina Velikyan, Anders Sundin, Mark Lubberink, Mattias Sandstrom, Ulrike Garske-Román, Hans Lundqvist, Dan Granberg and Barbro Eriksson

Journal of Nuclear Medicine May 1, 2013, 54 (supplement 2) 1863;

Main menu

User menu

Search

More articles from MTA II: Endocrine/Neuroendocrine Posters

Pages